A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2019
Price : $35 *
At a glance
- Drugs PU H71 (Primary) ; Ruxolitinib
- Indications Myelofibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Samus Therapeutics
- 25 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 13 Jun 2018 According to a Samus Therapeutics media release, first patient has been dosed in this trial.